Corneal Refractive Therapy Market to Reach $2.9 Billion by 2032

Corneal refractive therapy is entering a phase of accelerated clinical and commercial adoption, driven by rising myopia prevalence and pressure on traditional optical margins. Specialty practices increasingly reposition CRT as a premium, technology-enabled modality that strengthens profitability while addressing long-term vision health needs.